Gilead Sciences (GILD) Initiates Phase 3 Study for novel Coronavirus vaccine

Gilead Sciences (NASDAQ: GILD) today announced the initiation of two phase 3 clinical studies for the novel Coronavirus. The study aims to evaluate the efficacy of remdesivir in adults diagnosed with COVID-19. Find winning trades …

Gilead Sciences (GILD) Initiates Phase 3 Study for novel Coronavirus vaccine Read More »